MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Urodynamic study to distinguish multiple system atrophy from Parkinson’s disease

KW. Park, JH. Shin, NR. Choi, SY. Jo, MS. Choo, SJ. Chung (Seoul, Republic of Korea)

Meeting: 2019 International Congress

Abstract Number: 1608

Keywords: Multiple system atrophy(MSA): Clinical features, Urogenital dysfunction

Session Information

Date: Wednesday, September 25, 2019

Session Title: Non-Motor Symptoms

Session Time: 1:15pm-2:45pm

Location: Agora 3 West, Level 3

Objective: To evaluate differences in urodynamic findings between multiple system atrophy (MSA) and Parkinson’s disease (PD) and identify the utility of urodynamic parameters for the differential diagnosis.

Background: Urinary dysfunction is one of the differential diagnostic clues to differentiate MSA from PD. Severe symptomatic autonomic failure including urinary incontinence a prognostic indicator of survival in MSA. Urodynamic study is a gold standard tool for evaluating voiding dysfunction in patients with neurologic deficits. However, little is known about the urodynamic feature of MSA except for large post-void residual volume.

Method: We retrospectively reviewed patients with probable MSA or PD who underwent urodynamic studies from January 2011 to August 2018. Patients with possible MSA or PD, secondary Parkinsonism, any history of pelvic operation and radiation therapy were excluded. Primary aim was to compare the parameters of urodynamic studies between MSA and PD. Secondary aim was to compare the sensitivity and specificity of the major urodynamic parameters for the differential diagnosis between MSA and PD.

Results: A total 107 MSA patients and 112 PD patients were included. In uroflowmetry, MSA patients showed lower maximal flow rate (4.0±5.8 ml/s vs. 9.1±8.3 ml/s, p<0.001) and larger post-void residual (290.8±196.7 ml vs. 134.0±188.1 ml, p<0.001) compared with PD patients. In pressure flow study, MSA patients showed lower maximal flow rate (3.5 ± 5.0 ml/s vs. 8.2 ± 7.4 ml/s, p<0.001) and larger post-void residual (361.5 ± 169.6 ml vs. 146.1 ± 178.0 ml, p<0.001), decreased compliance (44.9% vs. 10.7%, p<0.001),  impaired contractility (24.9±33.8 vs. 65.7±51.1, p<0.001) and lower PdetQmax (7.4 ± 14.7 vs 24.9 ± 27.7, p<0.001) compared with PD patients. Detrusor overactivity and associated leakage was more prominent in PD compared with MSA (36% vs. 88%, p<0.001). Post-void residual from pressure-flow study was the only parameter with AUC value > 0.8 among the seven parameters, followed by PdetQmax.

Conclusion: MSA patients showed lower maximal flow rate, larger post-void residual with decreased compliance and impaired contractility, whereas PD patients had higher incidence of detrusor overactivity and associated leakage. For differential diagnosis, post-void residual from pressure-flow study provided the best sensitivity and specificity.

To cite this abstract in AMA style:

KW. Park, JH. Shin, NR. Choi, SY. Jo, MS. Choo, SJ. Chung. Urodynamic study to distinguish multiple system atrophy from Parkinson’s disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/urodynamic-study-to-distinguish-multiple-system-atrophy-from-parkinsons-disease/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/urodynamic-study-to-distinguish-multiple-system-atrophy-from-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley